For women and men with triple-negative breast cancer, chemotherapy has been the primary treatment option. But as scientists learn more about subtypes of triple-negative breast cancer, clinical trials can better match new targeted therapies with specific triple-negative patients. These advances are what led to the FDA approval in March 2019 of the PD-L1 inhibitor atezolizumab (Tecentriq®) to treat women and men with metastatic triple-negative breast cancer whose tumors test positive for PD-L1. And we can expect to see more trials that target specific subtypes of triple-negative cancer in the future.
- Cancer Therapy Advisor: The First Targeted Therapy For PD-L1+ Metastatic Triple-Negative Breast Cancer
- Breast Cancer Research: Identification of Three Subtypes of Triple-Negative Breast Cancer
- Nature Research: A Novel Approach to Triple Negative Breast Cancer Molecular Classification
- Targeted Oncology: Late Line Management of Metastatic Triple-Negative Breast Cancer
- Practice Update: Ladiratuzumab Vedotin Plus Pembrolizumab for Advanced TNBC
- Metastatic Trial Search: Find trials for metastatic triple negative breast cancer
Last Modified on February 10, 2021